Exact Sciences (EXAS) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. JNJ
5. PLTR
6. META
7. QQQ
8. LDOS
9. HUM
10. CSCO

Go back to Exact Sciences (EXAS) Misses Q3 EPS by 1c

Cologuard® Growth Trajectory Increases to 34,000 Completed Tests, Generates $12.6M in Revenue in Third Quarter 2015

October 29, 2015 5:00 AM EDT

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company continued its strong performance during the third quarter ended Sept. 30, 2015, completing 34,000 Cologuard tests, an increase of 60 percent from the second quarter, which resulted in $12.6 million in revenues. The cumulative number of ordering physicians grew to 21,000 during the quarter, an increase of 42 percent.

We remain pleased with the growing traction that Cologuard is gaining in the colon cancer screening market, said Kevin T. Conroy, chairman and CEO of Exact Sciences. Cologuards continued growth is built on its outstanding performance... More